HCPLive Network

Victories and Challenges in Hepatitis Testing: New USPSTF Guidelines and the Affordable Care Act

 
During a seminar at the 2013 United States Conference on AIDS, Ryan Clary presented information about how the lessons learned from HIV advocacy translate into viral hepatitis advocacy. Clary is Director of Policy and Programs at the National Viral Hepatitis Roundtable, a coalition of about 200 organizations across the country fighting on behalf of people with hepatitis B and C.
 
Around five million Americans have hepatitis B or C. “The really scary part is that up to 70 percent of these people don’t know they have it,” said Clary. Since the disease often isn’t accompanied by any symptoms early on, many people present with symptoms of very late stage liver cancer. More than 15,000 people die of hepatitis B or C in the US every year.
 
Clary explained that the demographics behind hepatitis C are important, since 75% of cases are found in people born between 1945 and 1965 (ie, the Baby Boomers). African Americans, Asians, Latinos, people with HIV, veterans, prisoners, and homeless people are also affected in greater numbers. Of people with HIV in the US, about 25% are also affected with hepatitis C, and about 10% are infected with hepatitis B. This is one of the main reasons liver failure is a major cause of death in people with HIV.
 
According to Cleary, there are many similarities between the challenges faced by people who have HIV and those who have viral hepatitis. Both groups face social stigma, and may or may not know their status, and the disease disproportionately affects similar communities. Many services and clinics have begun integrating HIV and hepatitis treatment.


Further Reading
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
Among individuals without diabetes, a higher level of hemoglobin A1c is associated with advanced coronary artery calcification progression, according to research published online Oct. 16 in Diabetes Care.
Women aren't treated with dialysis as often as men when they have end-stage renal disease, according to research published Oct. 28 in PLOS Medicine.
More Reading
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.